NCT04318938: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping |
|
|
| Active, not recruiting | 2 | 118 | Europe | Brigatinib, Study treatment, Tyrosine kinase inhibitor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Takeda | NSCLC | 01/26 | 01/26 | | |
LePaLuMo, NCT06252233: Improvement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer |
|
|
| Recruiting | N/A | 220 | Europe | patient- and physician-centered QoL monitoring, Placebo | University of Bayreuth, University of Regensburg, Tumor Center Regensburg, Center for Quality Management and Health Services Research, G-BA Innovationsfonds, University Hospital Regensburg, Center for Clinical Trials, Bavarian Cancer Registry, Bavarian Health and Food Safety Authority | Lung Cancer, Quality of Life | 02/25 | 08/25 | | |
